Abstract
This report explores the increasing link between autoimmune disorders and neurodiverse conditions, particularly Autism Spectrum Disorder (ASD) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). A small study included aims to evaluate the effectiveness of intramuscular immunoglobulins (IMIG) in reducing neuroinflammation in these conditions. Seven children with Autism Spectrum Disorder and five with Pediatric Acute-onset Neuropsychiatric Syndrome were treated with monthly intramuscular immunoglobulins injections. Parents rated improvements in concentration, communication, and behaviour for Autism Spectrum Disorder, and reduction of tics for Pediatric Acute-onset Neuropsychiatric Syndrome. Results showed notable improvements, particularly in Pediatric Acute-onset Neuropsychiatric Syndrome patients. Intramuscular immunoglobulins offer a promising, cost-effective alternative to intravenous immunoglobulins (IVIG) in managing autoimmune neuroinflammation, warranting further investigation.